|
Department
of Biomedical and Pharmaceutical Sciences University of Rhode Island, Kingston, Rhode Island |
| Home | Research | Publications | People | Photo Gallery | Contacts |
|
106. Agarwal, H. K., Chhikara, B. S., Hanley, M.
J., Ye,
G., Doncel, G. F., Parang, K. Synthesis
and biological evaluation of fatty acyl ester
derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. J.
Med. Chem. (2012) DOI:
10.1021/jm300492q. 105. Agarwal, H.
K., Chhikara, B. S., Quiterio, M., Doncel, G. F., Parang, K. Synthesis
and anti-HIV activities of glutamate and peptide conjugates of
nucleoside
reverse transcriptase inhibitors. J.
Med. Chem. (2012) 55,
2672-2687. 104. Chhikara, B. S.,
Mandal, D., Parang, K. Synthesis, anticancer activities, and cellular
uptake
studies of lipophilic derivatives of doxorubicin succinate. J. Med.
Chem. (2012) 55, 1500-1510. 103. Munthayala, M.,
Chhikara, B., Parang, K., Kumar, A. Ionic liquid-supported
synthesis of
sulfonamides and carboxamides. ACS Combinatorial Science (2012)
14,
60-65. 102. Kameshwara Rao, V.,
Chhikara, B.S., Tiwari, R., Nasrolahi Shirazi, A., Parang, K., Kumar,
A.
One-pot regioselective synthesis of tetrahydroindazolones and
evaluation of
their anti-proliferative and Src kinase inhibitory activities. Bioorg.
Med.
Chem. Lett. (2012) 22, 410-414. 101. Rao, M. S.,
Chhikara, B. S., Tiwari, R., Shirazi, A. N., Parang, K., Kumar, A.
Microwave-assisted and scandium triflate catalyzed synthesis of
tetrahydrobenzo[α]xanthen-11-ones. Monatsh. Chem. (2012)
143,
263-268. 100. Agarwal, H. K.,
Doncel, G. F., Parang, K. Synthesis and anti-HIV activities of
Suramin
conjugates of 3′-fluoro-2′,3′-dideoxythymidine and
3′-azido-2′,3′-dideoxythymidine. Med. Chem. 2012,
8,
193-197. 99. Muthyala, M. J.,
Chhikara, B. S., Parang, K., Kumar, A. Ionic-liquid-supported
1,5,7-triazabicyclo[4.4.0]dec-5-ene— An efficient and recyclable
organocatalyst
for Michael addition to α,β-unsaturated ketones. Can.
J. Chem. (2012) 90,
290-297. 98. Tiwari, R., Parang
K. Conformationally constrained peptides as protein tyrosine kinase
inhibitors. Current Pharmaceutical Design (2012), in
press,
PMID 22571654. 97. Mandal, D.,
Nasrolahi Shirazi, A., Parang, K. Cell-penetrating homochiral cyclic
peptides
as nuclear-targeting molecular transporters. Angew. Chem. Int. Ed. (2011)
50, 9633-9637. 96. Fallah-Tafti, A.,
Foroumadi, A., Tiwari, R., Shirazi, A. N., Hangauer, D. G., Bu, Y.,
Akbarzadeh,
T., Parang, K., Shafiee, A. Thiazolyl N-benzyl-substituted
acetamide
derivatives: Synthesis, Src kinase inhibitory and anticancer
activities. Eur.
J. Med. Chem. (2011) 46, 4853-4858. 95. Kathuria, A.,
Jalal, S., Tiwari, R., Nasrolahi Shirazi, A., Gupta, S., Kumar, S., Parang,
K., Harma, S. K.
Substituted coumarin derivatives:
Synthesis and
evaluation of antiproliferative and Src kinase inhibitory activities. Chemistry
Biology Interface (2011) 1 (2), 279-296. 94. Kumar, A., Ahmad, I,
Chhikara, B. S., Tiwari, R., Mandal, D., Parang, K. Synthesis of
3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of
their
Src kinase inhibitory and anticancer activities. Bioorg. Med. Chem.
(2011) 21, 1342-1346. 93. Agarwal, H. K., Loethan,
K., Mandal, D., Doncel, G. F. Parang, K. Synthesis and anti-HIV
activities of
fatty acyl ester derivatives of 2',3'-didehydro-2',3'-dideoxythymidine.
Bioorg.
Med. Chem. (2011) 21, 1917-1921. 92. Chhikara, B. S., St.
Jean, N., Mandal, D., Kumar, A., Parang, K. Fatty-acyl amide
derivatives of
doxorubicin: Synthesis and in vitro anticancer activities. Eur. J.
Med.
Chem. (2011) 46, 2037-2042. 91. Ahmadibeni, Y.,
Tiwari, R., Swepson, C., Pandhare, J., Dash, C., Doncel, G. F., Parang,
K.
Synthesis and anti-HIV activities of bis-(cycloSaligenyl)
pronucleotides
derivatives of 3'-fluoro-3'-deoxythymidine and
3'-azido-3'-deoxythymidine. Tetrahedron
Lett. (2011) 52, 802-805. 90. Kumar, D., Buchi
Reddy, V., Kumar, A., Mandal, D., Tiwari, R., Parang, K. Click
chemistry
inspired one-pot synthesis of 1,4-disubstituted 1,2,3-triazoles and
their Src
kinase inhibitory activity. Bioorg. Med. Chem. Lett. (2011)
2, 449-452. 89. Gupta, A., Mandal,
D., Ahmadibeni, Y., Parang, K., Bothun, G. Hydrophobicity drives the
non-specific
cellular uptake of short cationic peptide ligands. Eur. Biophysics
J. (2011) 40, 727-736. 88. Fallah-Tafti, A.,
Tiwari, R., Shirazi, A. N., Akbarzadeh, T., Mandal, D., Shafiee, A.,
Parang, K.
, Foroumadi, A. 4-Aryl-4H-Chromene-3-carbonitrile derivatives:
Evaluation of
Src kinase inhibitory and anticancer activities. Med. Chem. (2011)
7,
466-472. 87.
Dash, C., Ahmadibeni, Y., Hanley, M. J., Pandhare, J., Gotte, M., Le
Grice, S.
F. J., Parang, K. Inhibition of multi-drug resistant HIV-1 reverse
transcriptase by nucleoside beta-triphosphates. Bioorg. Med. Chem.
Lett. (2011) 21, 3519-3522. 86. Rao, V. K.,
Chhikara, B. S., Nasrolahi Shirazi, A. N., Tiwari, R., Parang, K.,
Kumar, A.
3-Substituted indoles: One-pot synthesis and evaluation of anticancer
and Src
kinase inhibitory activities. Bioorg. Med. Chem. (2011)
21,
3511-3514. 85. Chhikara, B. S.,
Parang, K. Development of cytarabine prodrugs and delivery systems for
leukemia
treatment. Expert Opin. Drug Del. (2010) 7,
1399-1414. 84.
Agarwal, H. K., Kumar, A., Doncel, G. F., Parang K. Synthesis,
antiviral and
contraceptive activities of nucleoside-sodium cellulose sulfate acetate
and
succinate conjugates. Bioorg. Med. Chem. Lett. (2010) 20,
6993-6997. 83. Chhikara, B. S.,
Mandal, D., Parang, K. Synthesis and evaluation of fatty acyl ester
derivatives
of cytarabine as anti-leukemia agents. Eur. J. Med. Chem. (2010)
45,
4601-4608. 82. Sharma, D., Bhatia,
S., Sharma, R. K., Tiwari, R., Olsen, C. E., Mandal, D., Lehmann, J.,
Parang,
K., Parmar, V. S., Prasad, A. S. Synthesis, Src kinase inhibitory and
anticancer activities of 1-substituted
3-(N-alkyl-N-phenylamino)propane-2-ols. Biochimie ( 2010)
92, 1164-1172. 81. Ahmadibeni, Y.,
Dash, C., Le Grice, S. F. J., Parang K. Solid-phase synthesis of
5'-O-beta,gamma-methylenetriphosphate derivatives of nucleosides and
evaluation
of their inhibitory activity against HIV-1 reverse transcriptase. Tetrahedron
Lett. (2010) 51, 3010-3013. 80. Tiwari, R., Brown,
A., Narramaneni, S., Sub, G., Parang, K. Synthesis and evaluation of
conformationally constrained peptide analogues as the Src SH3 domain
binding
ligands. Biochimie (2010) 92, 1153-1163. 79. Ahmadibeni, Y.,
Dash, C., Hanley, M. J., Le Grice, S. F. J., Agarwal, H. K., Parang K.
Synthesis of nucleoside 5'-O-alpha,beta-methylene-betatriphosphates and
evaluation of their potency towards inhibition of HIV-1 reverse
transcriptse. Org.
Biomol. Chem. (2010) 8, 1271-1274.. 78. Ye, G., Gupta, A.,
Delluca, R., Parang, K., Bothun, G. D. Bilayer distribution and
liposome
restructuring by a homologous series of small Arg-Rich synthetic
peptides. Colloids
and Surfaces B.:Biointerfaces (2010) 76, 76-81. 77. Penugonda, S.,
Agarwal, H. K., Parang, K., Mehvar, R. Plasma pharmacokinetics and
tissue
disposition of novel dextran-methylprednisolone conjugates with peptide
linkers
in rats. J. Pharmaceutical Sci. (2010), 99,
1627-1637. 76. Tiwari, R., Parang
K. Protein conjugates of SH3 domain ligands and ATP-competitive
inhibitors as
bivalent inhibitors of protein kinases. ChemBioChem (2009) 10,
2445-2448. 75. Carballeira, N. M.,
Miranda, C., Parang, K. The first total synthesis of the (
)-4-methoxydecanoic
acid: a novel antifungal fatty acid. Tetrahedron Lett. (2009)
50,
5699-5700. 74. Ye, G., Schuler, A.,
Ahmadibeni, Y., Morgan, J. R., Faruqui, A., Huang, K., Sun, G., Zebala,
J. A.,
Parang, K. Synthesis and evaluation of peptides containing
iminodiacetate
groups as binding ligands of the Src SH2 domain. Bioorg. Chem.
(2009) 37, 133-142. 73. Ahamadibeni, Y.,
Tiwari, R., Sun, G., Parang, K. Synthesis of nucleoside mono-, di-, and
triphosphoramidates from solid-phase cycloSaligenyl phosphitylating
reagents. Org.
Lett. (2009) 11, 2157-2160. 72.
Ahmadibeni,
Y., Parang, K. Solid-supported reagents for synthesis of nucleoside
monothiophosphates, dithiodiphosphates, and trithiotriphosphates. Curr.
Protoc. Nucleic Acid Chem.(2009) Chapter 13:Unit13.9. 71.
Parang, K., Doncel, G., Agarwal, H. K. Substituted
nucleoside
derivatives and
antiviral and antimicrobial properties. PCT Int. Appl. (2009)
WO 2009009625. 70. Agarwal,
H. K.,
Doncel, G.,
Parang, K. Synthesis and anti-HIV activities of phosphate triester
derivatives
of 3′-fluoro-2′,3′-dideoxythymidine and
3′-azido-2′,3′-dideoxythymidine. Tetrahedron
Lett. (2008) 49, 4905-4907. 69. Ye, G., Tiwari, R.,
Parang K. Development of Src tyrosine kinase substrate binding site
inhibitors. Curr. Opin. Investig. Drugs (2008) 9,
605-613. 68. Ahmadibeni, Y.,
Parang, K. Solid-supported diphosphitylating and triphosphitylating
reagents
for nucleoside modification. Curr. Protoc. Nucleic Acid Chem. (2008)
Chapter
13:Unit13.8. 67. Penugonda, S.,
Kumar, A., Agarwal, H. K., Parang, K., Mehvar, R. Synthesis and in
vitro
characterization of novel dextran-methylprednisolone conjugates with
peptide
linkers: Effects of linker length on hydrolytic and enzymatic release
of
methylprednisolone and its peptidyl intermediates. J. Pharm. Sci.
(2008) 97, 2649-2664. 66. Ahmadibeni, Y.,
Parang, K. Solid-phase synthesis of symmetrical
5’,5’-dinucleoside mono-, di-,
tri-, and tetraphosphodiesters. Org. Lett. (2007) 9,
4483-4486. 65. Bhandari, R.,
Saiardi, A., Ahmadibeni, Y., Snowman, A. M., Resnick, A. C.,
Kristiansen, T.
Z., Molina, H., Pandey, A., Werner, Jr. J. K., Juluri, K. R., Xu, Y.,
Prestwich, G. D., Parang, K., Snyder, S. H. Protein pyrophosphorylation
by
inositol pyrophosphates is a posttranslational event. Proc. Nat.
Acad. Sci. U.S.A. (2007) 104, 15305-15310. 64. Chimalakonda, C.,
Agarwal, H., Kumar, A., Parang, K., Mehvar, R. Synthesis, analysis, in
vitro
characterization, and in vivo disposition of a lamivudine-dextran
conjugate for
selective antiviral delivery to the liver. Bioconjugate Chem. (2007)
18, 2097-2108. 63. Ye, G., Nam, N. H.,
Saleh,A., Kumar, A., Sun, G., Shenoy, D. B.,
Amiji, M.
M., Parang,K. Cellular delivery of phosphopeptides with
tripodal peptide
analogues. J. Med. Chem. (2007) 50, 3604-3617. 62. Ahmadibeni, Y.,
Hanley, M., White, M., Ayrapetov, M., Lin, X., Sun, G., Parang, K.
Metal-binding properties of a dicysteine-containing motif in protein
tyrosine
kinases. ChemBioChem (2007) 8, 1592-1605. 61. Carballeira, N. M.,
O’Neil, R., Parang, K. Synthesis and antifungal
properties of
alpha-methoxy and alpha-hydroxyl substituted 4-thiatetradecanoic acids.
Chem.
Phys. Lipids (2007) 150, 82-88. 60. Ahmadibeni, Y.,
Parang, K., Synthesis and evaluation of oligodeoxynucleotides
containing
diphosphodiester internucleotide linkages. Angew. Chem. Int. Ed. (2007)
46, 4739-4743. 59. Kumar, A., Wang, Y.,
Lin, X., Sun, G., Parang, K. Synthesis and evaluation of
3-phenylpyrazolopyrimidine-peptide conjugates as Src tyrosine kinase
inhibitors. ChemMedChem (2007) 2, 1346-1360. 58. Agarwal, H. K.,
Parang, K. Application of solid-phase chemistry for the synthesis of
3’-fluoro-3’-deoxythymidine. Nucleosides,
Nucleotides& Nucleic Acids (2007)
26, 317-322. 57. Parang, K.,
Ahmadibeni, Y. Solid-phase synthesis of modified oligonucleotides
containing
diphosphodiester inter-nucleotide linkages. PCT Int. Appl. (2007)
WO 2007030227. 56. Gu,X., Wang, Y.,
Kumar, A., Ye, G., Parang, K., Sun, G. Design
and
evaluation of hydroxamate derivatives as metal-mediated inhibitors of a
protein
tyrosine kinase. J. Med. Chem. (2006) 49, 7532-7539. 55. Kumar, A., Ye, G.,
Wang, Y., Lin, X., Sun, G., Parang, K. Synthesis and structure-activity
relationships of linear and conformationally constrained peptide
analogs of
CIYKYY as Src tyrosine kinase inhibitors. J. Med. Chem. (2006)
49, 3395-3401. 54. Carballeira, N. M.,
Sanabria, D., Cruz, C., Parang, K., Wan, B., Franzblau, S.
2,6-Hexadecadiynoic
acid and 2,6-nondecadiynoic acid – Novel synthesized acetylenic
fatty acids as
potent antifungal agents. Lipids (2006) 41,
507-511. 53. Ahmadibeni, Y.,
Parang, K. “Application of a solid-phase beta-triphosphitylating
reagent
in the synthesis of nucleoside beta-triphosphates. J. Org. Chem.
(2006)
71, 5837-5839. 52. Ahmadibeni, Y.,
Parang, K. Solid-phase synthesis of dinucleoside and
nucleoside-carbohydrate
phosphodiesters and thiophosphodiesters. J. Org. Chem. (2006)
71,
6693-6696. 51. Lee, S., Ayrapetov,
M. K., Kemble, D., Parang, K., Sun, G. Docking-based substrate
recognition by
the catalytic domain of a protein tyrosine kinase, the C-terminal Src
kinase. J.
Biol. Chem. (2006) 281, 8183-8189. 50. Lin, X., Wang, Y.,
Ahmadibeni, Y., Parang, K., Sun, G. Structural basis for domain-domain
communication in a protein tyrosine kinase, Csk. J. Mol. Biol. (2006)
357, 1263-1273. 49. Ayrapetov, M. K.,
Wang, Y.-H., Xiaofeng, L., Gu X., Parang, K., Sun, G.
Conformational
basis for SH2-pTYR527 binding in Src inactivation. J. Biol. Chem.
(2006) 281, 23776-23784. 48. Kumar, A., Ye, G.,
Ahmadibeni, Y., Parang, K. Synthesis of polymer-bound
4-acetoxy-3-phenylbenzaldehyde derivatives: Applications in solid-phase
organic
synthesis. J. Org. Chem. (2006) 71, 7915-7918. 47. Parang, K. Editor.
Novel approaches in designing anti-HIV microbicides and anti-HIV
Agents. Curr.
Pharm. Des. (2005) 11, 123 pp. 46. Ahmadibeni, Y.,
Parang, K. Selective diphosphorylation, dithiodiphosphorylation,
triphosphorylation, and trithiotriphosphorylation of unprotected
carbohydrates
and nucleosides. Org. Lett. (2005) 7, 5589-5592. 45. Parang, K., Sun, G.
Recent advances in the discovery of Src kinases inhibitors. Expert
Opin.
Ther. Patents (2005) 15, 1183-1207. 44. Ye, G., Ayrapetov,
M., Nam, N. H., Sun, G., Parang, K. Solid-phase binding assays of
peptides
using EGFP-Src SH2 domain fusion protein and biotinylated Src SH2
domain. Bioorg.
Med. Chem. Lett. (2005) 15, 4994-4997. 43. Carballeira, N. M.,
O'Neill, R., Parang, K. Total synthesis and further
scrunity of the
in vitro antifungal activity of 6-nonadecynoic acid. Arch.
Pharm.-Pharm.
Med. Chem. (2005) 338, 441-443. 42. Ayrapetov, M. K.,
Nam, N. H., Ye, G. Kumar, A., Parang, K., Sun, G. Functional diversity
of Csk,
Chk, and Src SH2 domains due to a single residue variation. J.
Biol. Chem. (2005) 280, 25780-25787. 41. Parang, K., Nam, N.
H. Sardari, S. Preparation of azole monosaccharide as antifungal
agents. PCT
Int. Appl. 006860 (2005) 62 pp, U.S. Patent 7,351,731,
April
2008. 40. Ahmadibeni, Y.,
Parang, K. Polymer-bound oxathiaphospholane: A solid-phase reagent for
regioselective monothiophosphorylation and monophosphorylation of
unprotected
nucleosides and carbohydrates. Org. Lett. (2005) 7,
1955-1958. 39. Carballeira, N. M.,
O'Neill, R., Parang K. Racemic and optically active
2-methoxy-4-oxatetradecanoic acids: Novel synthetic fatty acids with
selective
antifungal properties. Chem. Phys. Lipids (2005) 136,
47-54. 38. Parang, K., Sun, G.,
Kumar, A., Nguyen, N. H., Wang, Y.-H., Ye, G. Bisubstrate inhibitors of
protein
tyrosine kinases as therapeutic agents. PCT Int. Appl. WO
117932 (2005),
74 pp. 37. Hines, A. C.,
Parang, K., Kohanski, R. A., Hubbard, S. R., Cole, P. A. Bisubstrate
analog
probes for the insulin receptor protein tyrosine kinase: Molecular
yardsticks
for analyzing catalytic mechanism and inhibitor design. Bioorg.
Chem. (2005) 33, 285-297. 36. Lin, X., Ayrapetov,
M. K., Lee, S., Parang, K., Sun, G. Probing the communication between
the
regulatory and catalytic domains of a protein tyrosine kinase, Csk. Biochemistry
(2005) 44, 1561-1567. 35. Ahmadibeni, Y.,
Parang, K. Solid-phase reagents for selective monophosphorylation of
carbohydrates and nucleosides. J. Org. Chem. (2005)
70,
1100-1103. 34. Parang, K., Sun, G.
Protein kinase inhibitors in drug discovery. Drug Discovery Handbook,
2005,
Wiley-Interscience, New Jersey, Ed. Gad, S. C. 1191-1257. 33. Parang, K., Sun, G.
Design strategies for protein kinases inhibitors. Current Opinions
In Drug
Discovery (2004) 7, 630-638. 32. Nam, N. H., Lee, S.,
Ye, G., Sun, G., Parang, K. ATP-phosphopeptide conjugates as inhibitors
of Src
tyrosine kinases. Bioorg. Med. Chem. (2004) 12,
5753-5766. 31. Nam, N. H., Sardari,
S., Selecky, M., Parang, K. Carboxylic acids and phosphate ester
derivatives of
fluconazole: synthesis and antifungal activities. Bioorg. Med. Chem.
(2004) 12, 6255-6269. 30. Schmidt, B.,
Jiricek, J., Titz, A., Ye, G., Parang, K. Copper dipicolinates as
peptidomimetic ligands for the Src SH2 domain. Bioorg. Med. Chem.
Lett. (2004) 14, 4203-4206. 29. Nam, N. H., Pitts,
R., Sun, G., Sardari, S., Tiemo, A., Xie, M., Yan, B., Parang, K.
Design of
tetrapeptide ligands as inhibitors of the Src SH2 domain. Bioorg.
Med. Chem. (2004) 12, 779-787. 28. Nam, N.-H., Ye, G.,
Sun, G., Parang, K. Conformationally constrained peptide analogues of
pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding. J.
Med. Chem. (2004) 47, 3131-3141. 27. Carballeira, N. M.,
Ortiz, D., Parang, K., Sardari, S. Total synthesis and in vitro
antifungal activity of 2-methoxytetradecanoic acid. Arch.
Pharm.-Pharm. Med.
Chem. (2004) 337, 152-155. 26. Force, T., Kuida,
K., Parang, K., Kyriakis, J. M. Inhibitors of protein kinase signaling
pathways: emerging therapies for cardiovascular disease. Circulation
(2004) 109, 1196-1205. 25. Lee, S., Lin, X.,
Nam, N. H., Parang, K., Sun, G. Determination of the substrate-docking
site of
protein tyrosine kinase Csk. Proc. Nat. Acad. Sci. U.S.A. (2003)
100, 14707-14712. 24. Sardari, S.,
Pourmorad, F., Tiemo, A., Nam, H., Parang, K. Protein
kinases and
their modulation in the central nervous system. Current Medicinal
Chemistry-CNS (2003) 3, 341-364. 23. Nam, N. H., Sardari,
S., Parang, K. Reactions of solid supported reagents and solid
supports
with alcohols and phenols through their hydroxyl functional group. J.
Comb.
Chem. (2003) 5, 479-546. 22. Parang, K., Preface,
Anti-HIV design, Bentham Science Publishers, Hilversum, Current
Pharm.
Design (2003) 9, 22. 21. Nam, N. H., Parang,
K. Current Drug Targets for Anticancer Drug Discovery. Current Drug
Targets (2003), 4, 159-179. 20. Parang, K., Cole, P.
A. Bisubstrate inhibitors of protein kinases. Pharmacology and
Therapeutics (2002) 93, 145-157. 19. Parang, K.
Polymer-supported reagents for methylphosphorylation and
phosphorylation of Carbohydrates. Bioorg. Med. Chem. Lett. (2002)
12,
1863-1866. 18. Parang, K., Kohn, J.
A., Saldahna, A., Cole, P. A. Development of photo-crosslinking
reagents for
protein kinase-substrate interactions. Febs Letters (2002)
520,
156-160. 17. Parang, K., Preface,
Anti-HIV design, Bentham Science Publishers, Hilversum, Current
Pharm.
Design (2002) 8, 8. 16. Parang, K.,
Fournier, E. J.-L., Hindsgaul, O. A solid phase reagent for the capture
phosphorylation of carbohydrate and nucleosides. Org. Lett. (2001)3,
307-309. 15. Courtney, A., Cole,
P. A., Parang, K., Ablooglu, A., Kohanski, R. Bisubstrate inhibitors of
kinases. PCT Int. Appl. WO 0170770 (2001) , 39 pp,US
Patent
7,045,617 B2 May 2006. 14. Parang, K., Till, J.
H., Ablooglu, A. J., Kohanski, R. A., Hubbard, S. R., Cole, P. A.
Mechanism-based design of a protein kinase inhibitor. Nature
Structural
Biology (2001) 8, 37-41. 13. Parang, K., Wiebe,
L. I., Knaus, E. E. Novel approaches in designing prodrugs of AZT. Current
Medicinal Chemistry (2000) 7, 995-1039. 12. Kim, K., Parang, K.,
Lau, O. D., Cole, P. A. Tyrosine analogs as alternative substrates for
protein
tyrosine kinase Csk: insights into substrate selectivity and catalytic
mechanism. Bioorg. Med. Chem. (2000) 8,
1263-1268. 11. Ablooglu, A. J.,
Till, J. K., Kim, K., Parang, K., Cole, P. A., Hubbard, S. R.,
Kohanski, R. A.
Probing the catalytic mechanism of the insulin receptor kinase with a
tetrafluorotyrosine-containing peptide substrate. J. Biol. Chem. (2000)
275, 30394-30398. 10. Parang, K., Wiebe,
L. I., Knaus, E. E., Huang, J. S., Tyrrell, D. L. In vitro
anti-hepatitis B virus activities of 5’-O-myristoyl
analogue derivatives
of 3’-fluoro-2’,3’-dideoxythymidine (FLT) and
3’-azido-2’,3’-dideoxythymidine
(AZT). J. Pharm. Pharmaceut. Sci. (1998) 1,
107-113. 9. Parang, K., Knaus, E.
E., Wiebe, L. I. Synthesis, in vitro anti-HIV activity, and
biological
stability of 5’-O-myristoyl analogue derivatives of
3’-fluoro-2’,3’-dideoxythymidine (FLT) as potential
prodrugs of FLT.
Nucleosides & Nucleotides (1998) 17, 987-1008. 8. Parang, K., Wiebe, L.
I., Knaus, E. E. In vivo pharmacokinetic parameters, liver and
brain
uptake of (±)-3’-azido-2’,3’-dideoxy-5’-O-(2-bromomyristoyl)thymidine
as
potential prodrug of 3’-azido-3’-deoxythymidine. J.
Pharm. Pharmacol. (1998) 50, 989-996. 7. Parang, K., Knaus, E.
E., Wiebe, L. I. Synthesis, in vitro anti-HIV
structure-activity
relationships and stability of 5’-O-myristoyl analogue
derivatives of
3’-azido-2’,3’-dideoxythymidine as potential prodrugs
of 3’-azido-2’,3’-dideoxythymidine
(AZT). Antiviral. Chem. Chemother. (1998) 9,
311-323. 6. Parang, K., Wiebe, L.
I., Knaus, E. E. Syntheses and biological evaluation of 5’-O-myristoyl
derivatives of thymidine against human immunodeficiency virus (HIV-1). Antiviral.
Chem. Chemother. (1997) 8, 417-427. 5. Parang, K., Wiebe, L.
I., Knaus, E. E., Huang, J. S., Tyrrell, D. L., Csizmadia, F. In
vitro
antiviral activities of myristic acid analogs against human
immunodeficiency
and hepatitis viruses. Antiviral Research(1997) 34,
75-90. 4. Parang, K., Knaus, E.
E., Wiebe, L. I., Sardari, S., Daneshtalab, M., Csizmadia, F. Synthesis
and
antifungal activities of myristic acid analogs. Arch. Pharm.-Pharm.
Med.
Chem. (1996) 329, 475-482. 3. Sharifan, A., Parang,
K., Zorrieh-Amirian, H., Nazarinia, M., Shafiee, A. Synthesis of
1-substituted
1,2,4-triazoles, imidazoles and benzimidazoles. J. Heter. Chem.
(1994) 31, 1421-1423. 2. Shafiee, A., Parang,
K., Khazen, M., Ghasemian, F. Synthesis of substituted 2-(1-methyl-5-
nitro-2-imidazolyl)quinolines. J. Heter. Chem. (1992) 29,
1859-1861. 1. Shafiee, A.,
Pirouzzadeh, B., Ghasemian, F., Parang, K. Synthesis of
2-acetyl-1-methyl
-5-nitroimidazole. J. Heter. Chem. (1992) 29,
1021-1023. |
